Related Experiment Video

Updated: Jun 24, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Management of chronic hepatitis B in children

Uzma Shah1, Deirdre Kelly, Mei-Hwei Chang

  • 1Harvard Medical School Dubai Center, Dubai Health Care City, Dubai, UAE.

Journal of Pediatric Gastroenterology and Nutrition
|March 27, 2009
PubMed

Insights

Hepatitis B virus (HBV) infection is a global health concern, particularly in children, leading to serious liver complications. This review details current recommendations for monitoring and treating chronic HBV in pediatric patients.

Area of Science:

  • Hepatology
  • Virology
  • Pediatrics

Background:

  • Hepatitis B virus (HBV) infection poses a significant global health challenge, causing severe liver diseases including cirrhosis and liver cancer.
  • High HBV prevalence is noted in Asia, Africa, southern Europe, and Latin America, with mother-to-infant transmission being a major contributor to chronic infections in endemic areas.
  • Childhood HBV infection is associated with a higher risk of persistent infection and long-term complications like hepatocellular carcinoma (HCC) compared to adult infections.

Purpose of the Study:

  • To review current guidelines for the management of chronic Hepatitis B virus infection in children.
  • To discuss the distinct phases of chronic hepatitis B and their implications for treatment.
  • To highlight the goals and limitations of antiviral therapy in preventing HBV-related liver disease.

Main Methods:

  • Literature review of current recommendations for monitoring and treating chronic Hepatitis B virus infection in pediatric populations.
  • Analysis of the epidemiology and transmission routes of HBV, with a focus on early childhood infection.
  • Discussion of the different phases of chronic hepatitis B: immune-tolerant, immune-active, and inactive.

Main Results:

  • Chronic HBV infection in children leads to a higher likelihood of persistent infection and severe outcomes such as liver cirrhosis and HCC.
  • Understanding the three phases of chronic hepatitis B is crucial for effective management and treatment response.
  • Current antiviral therapies aim to reduce viral replication and liver injury, as complete eradication of HBV remains challenging.

Conclusions:

  • Effective monitoring and timely antiviral treatment are essential for managing chronic Hepatitis B virus infection in children.
  • The review provides insights into optimizing therapeutic strategies to mitigate long-term liver complications in pediatric HBV patients.
  • Further research into therapies that can achieve HBV eradication is warranted to improve patient outcomes.

More Related Videos

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...